[4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries,[5] including the United States and Europe.

Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).

[13] During 2006 BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and APJ Abdul Kalam inaugurates India's Largest Biotech-Hub "Biocon Park".

[28] Another aspect of the deal involves Bicocon selling 15% of its biologics subsidiary to Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.

[34] She was named among Time magazine's 2010 100 most influential people in the world based not only on her contribution to the biotech industry but also because she gives back to the community.

In 2021 Biocon and Viatris received approval to launch Semglee, an insulin glargine-yfgn injection, which is the first interchangble biosimilar for diabetes in the United States.

[48] In July 2022, Syngene signed a 10-year agreement with Zoetis to manufacture the drug substance for Librela (bedinvetmab), a first-in-class monoclonal antibody used for treating osteoarthritis in dogs.

Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.

[52] Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi.

[54] In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes.

Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.

[30] In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases.

The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research.

Viatris will have exclusive commercialisation rights in the USA, Canada, Japan, Australia, New Zealand, EU, and European Free Trade Association countries through a profit-sharing arrangement with Biocon.

BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients with rheumatoid arthritis.

[30] In January 2018, Sandoz (a Novartis division) announced a global partnership with Biocon to develop, manufacture, and commercialize multiple biosimilars in immunology and oncology for patients worldwide.